IL-10 and an Anti–TGF-β MoAb Rescue ECs From PBMC-Caused Cell Cycle Arrest
| Treatment . | % of Cells3-150 (±SD) in . | ||
|---|---|---|---|
| . | G0/1-Phase . | S-Phase . | G2-Phase . |
| EC | 65.8 (±11.3) | 22.6 (±10) | 9.6 (±5.1) |
| EC+SN-PBMC | 77.2 (±8.4) | 4.8 (±3.4) | 15 (±5.4) |
| EC+SN-PBMC +IL-10 | 61.3 (±6.7) | 16.8 (±5.6)3-151 | 18.5 (±1.7) |
| EC+ SN-PBMC+anti – TGF-β | 62.3 (±2.2) | 16.3 (±12.4) | 16.7 (±12.3) |
| Treatment . | % of Cells3-150 (±SD) in . | ||
|---|---|---|---|
| . | G0/1-Phase . | S-Phase . | G2-Phase . |
| EC | 65.8 (±11.3) | 22.6 (±10) | 9.6 (±5.1) |
| EC+SN-PBMC | 77.2 (±8.4) | 4.8 (±3.4) | 15 (±5.4) |
| EC+SN-PBMC +IL-10 | 61.3 (±6.7) | 16.8 (±5.6)3-151 | 18.5 (±1.7) |
| EC+ SN-PBMC+anti – TGF-β | 62.3 (±2.2) | 16.3 (±12.4) | 16.7 (±12.3) |
ECs were either untreated (ECs) or incubated with cell-free supernatant of PBMCs (SN-PBMC) in the presence or absence of IL-10 (0.1 μg/mL) and the anti–TGF-β MoAb AB-101-NA.
Mean of at least three experiments.
P < .05 of proliferating cells after treatment with SN-PBMC in the presence of inhibitors versus SN-PBMC alone.